Back to top
more

Arcturus Therapeutics Holdings (ARCT)

(Delayed Data from NSDQ)

$26.98 USD

26.98
266,354

-0.95 (-3.40%)

Updated Apr 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 81.07% and 47.01%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.

The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie

Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.

Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up

Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.

New Strong Sell Stocks for August 10th

ARCT, AVY and ASB have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2023.

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -2,300% and 85.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Sundeep Ganoria  headshot

4 Biotech Stocks Set to Outpace Q2 Earnings Estimates

Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.

Community Health Systems (CYH) Reports Q2 Loss, Tops Revenue Estimates

Community Health Systems (CYH) delivered earnings and revenue surprises of 24.14% and 3.22%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -69.86% and 39.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -22.95% and 36.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 332.80% and 19.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?

Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 33.83% and 281.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -12.86% and 41.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Beats Q3 Earnings and Revenue Estimates

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 850% and 3.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 55.43% and 714.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2.33% and 23.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zealand Pharma AS (ZEAL) Stock Jumps 9.1%: Will It Continue to Soar?

Zealand Pharma AS (ZEAL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -50.39% and 60.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Surges 7.2%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 16.95% and 55.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?